News

Biopharma news, November 12, 2026

The most important drug and company news of November 12, 2026, ranked, each linked to its Gosset profiles.

  1. Approval

    Hengrui wins China approval for SHR-1918, first local ANGPTL3 antibody, in HoFH

    Chinese regulators approved SHR-1918 for patients aged 12 and up with homozygous familial hypercholesterolemia. In a phase 3 trial of 54 patients, LDL cholesterol dropped 58.8% at week 12 versus a 5.5% rise on placebo, with the effect holding to week 24. Most side effects were mild.

    Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

  2. Approval

    China Approves Eravacycline 100 mg

    China's National Medical Products Administration approved a new 100 mg strength of Everest Medicines' eravacycline product, 依嘉. The product's 50 mg strength was approved in China in 2023 for adults with complicated intra-abdominal infection. The company says the new strength may reduce preparation steps and drug waste for some patients and improve supply flexibility.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  3. Licensing & partnership

    Vor Bio adds RemeGen's long-acting BAFF/APRIL blocker RC298 to its license

    Vor Bio widened its licence from RemeGen to cover RC298, an early-stage long-acting blocker of both BAFF and APRIL, for markets beyond Greater China. Vor pays about $56 million upfront, $10 million of it in cash, plus development milestones of as much as $300 million. RemeGen will lead phase 1 after a planned China IND in early 2027.

    Source types: Press release · SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

  4. Pivotal readout

    Novartis's Rhapsido keeps working through one year in chronic inducible urticaria

    In the phase 3 RemIND study, remibrutinib responses held to week 52 across three urticaria subtypes: 46.8% in symptomatic dermographism, 83.3% in cold urticaria and 58.2% in cholinergic urticaria. Patients switched to the drug from placebo after 24 weeks improved too. Safety matched earlier experience, and more regulatory filings are planned.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  5. Approval

    China approves Lilly's orforglipron, its first oral GLP-1 pill for weight management

    Chinese regulators cleared orforglipron, a once-daily oral GLP-1 receptor agonist taken without food or water rules, for adult weight management. In ATTAIN-1 the top dose produced 12.4 kg average weight loss at 72 weeks, and 39.6% lost at least 15% versus 3.6% on placebo. Side effects were mostly mild gastrointestinal events during dose escalation.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  6. Pivotal readout

    Elafibranor normalizes ALP in most PBC patients in phase 3 ELSPIRE

    In ELSPIRE, which enrolled primary biliary cholangitis patients with only mildly raised alkaline phosphatase, 85.3% on elafibranor reached normal ALP by week 52 versus 23.3% on placebo, and the drug was well tolerated. The data were shown at this year's AASLD liver congress and are being filed with regulators.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  7. Pivotal readout

    enGene to start detalimogene BLA by year-end after new LEGEND bladder cancer data

    In the pivotal cohort of the phase 2 LEGEND trial in high-risk bladder cancer that no longer responds to BCG, 56% of 120 evaluable patients had a complete response, with a preliminary median duration of 10.1 months. Serious drug-related events hit 2% of patients. After meeting the FDA, enGene will begin its submission this year and aims to finish it by mid-2027.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  8. Licensing & partnership

    Blackstone commits up to $1.5 billion toward Pfizer's monthly GLP-1 berobenatide

    Funds managed by Blackstone will pay as much as $1.5 billion by 2028 toward development of berobenatide, Pfizer's investigational once-a-month GLP-1 agonist. Blackstone earns payments only if the drug wins US approval for chronic weight management and meets sales targets, while Pfizer keeps ownership and control. Pfizer has 10 phase 3 trials under way or planned.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  9. Pivotal readout

    Innovent Gastric Cancer Data

    At ESMO 2026, phase 3 G-HOPE-001 data showed median overall survival of 10.2 months with IBI343 versus 6.9 months with physician's choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. In a phase 1b study, first-line IBI363 plus XELOX achieved an 80% confirmed response rate and 12.4-month median progression-free survival in HER2-negative advanced disease. The expert describes precision targeting and combination treatment as promising directions, while noting that IBI363 remains at the proof-of-concept stage and needs phase 3 confirmation.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  10. Pivotal readout

    DBV presents further VITESSE phase 3 results for VIASKIN peanut patch in young children

    In the 654-child VITESSE trial in ages 4 to 7, 46.6% on the VIASKIN patch met the month-12 responder bar compared with 14.8% on placebo. New analyses showed milder reactions at food challenge and immune changes in line with allergen immunotherapy. Average adherence was 96.1%; the patch is still investigational.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call